April 24, 2021
As an X-linked disorder, Duchenne’s muscular dystrophy (DMD) primarily affects males, with an incidence of one in every 3500 males. Today, more than 40 companies are running clinical studies aimed at bringing novel therapeutics to market for DMD—a significant improvement from roughly 10 years ago where only three companies had ongoing therapeutic studies.